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Reply
We appreciate the comments of Dr. Joshi and colleagues regarding
our report on the cardiovascular risk assessment of candidates for
liver transplantation (1).
We agree that liver transplantation in patients with severe left
ventricular systolic dysfunction carries a higher risk for cardiovas-
cular complications and mortality. These patients should be
thoroughly evaluated, as we have described, and would benefit
from referral to higher volume transplantation centers with expe-
rience in caring for such patients. As noted in our report, and by
Joshi et al., there have been case reports of successful transplanta-
tion in such patients, often requiring combined liver and heart
transplantation (2). Several potential etiologies of systolic dysfunc-
tion in patients with end-stage liver disease have been described,
and some may be reversible (3,4). Therefore, we do not consider
severe systolic dysfunction to be an absolute contraindication to
liver transplantation. However, liver transplantation in this patient
type should be undertaken only at centers with advanced heart
failure programs.
With regard to the utility of the measurement of oxygen
consumption at peak exercise to assess aerobic capacity, this is
certainly another piece of information that can be added to the
cardiologist’s armamentarium when performing a cardiovascular
risk assessment of a liver transplantation candidate. In a multivar-
iate analysis, it was associated with 1-year survival and was also
associated with post-operative complications in sicker patients (5).
Although we do not believe that this should be a sole reason for
exclusion for liver transplantation candidacy, we agree that it may
aid in assessing cardiovascular risk.
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The Role of Platelet Function
Testing and Genotyping
in the Stented Patient
Treated With Clopidogrel
We read with interest the study of Campo et al. (1). Their
observation that P2Y12 reaction units (PRU) decreased at 1 month
compared to baseline in patients receiving clopidogrel undergoing
percutaneous coronary intervention (PCI) is similar to our report
in 2003 (2), where 30% of patients were resistant at 1 and 5 days
post-PCI, and 15% were resistant at 30 days. Similar observation
of lower prevalence of 30-day high platelet reactivity compared to
12 to 24 h post-stenting was also reported recently (3). We further
presented similar PRU levels at 24 h after 600 mg loading and just
before the last maintenance dose at 6 weeks (4). Mean PRUs at 8 h
after last maintenance dose decreased by 25. These findings
indicate the “booster” effect of the last maintenance dose by new
active metabolite generation. Therefore, clopidogrel response is
significantly influenced by measured time after clopidogrel admin-
istration even during the maintenance phase. In the study by
Campo et al. (1), a decrease in PRU levels at 1 month may be
partially related to measured time (25 PRU in stable patients).
However, Campo et al. (1) did not mention the timing of
measurements with respect to the last dose administration.
Another important issue is that the post-PCI event occurrence
reported by Campo et al. (1) is relatively discordant with most
PCI-related studies demonstrating more frequent events within 30
to 60 days post-PCI. Interestingly, the first ischemic event in
Campo et al. (1) occurred at 50 days post-PCI (estimated from
Fig. 3 of Campo et al. [1]).
In multivariate analysis, CYP2C19*17 variant and 30-day PRU
together were independent determinants of bleeding, implicating
that CYP2C19*17 effect on bleeding may be independent of
clopidogrel response, which requires further explanation. Although
platelet function testing and genotyping may play complementary
roles in tailoring antiplatelet therapy, numerous clinical factors
including drug-drug interaction may influence the magnitude of
platelet reactivity and clinical outcomes. In the future, a compre-
hensive algorithm including clinical as well as laboratory findings
may optimize outcomes in the era of potent P2Y12 inhibitors.
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Reply
We thank Dr. Jeong and colleagues for their comments with
regard to our study (1). We well know that previous studies
investigated on-clopidogrel platelet reactivity (PR) through
follow-up (2,3). Nevertheless, these findings were observations in
studies planned for other aims. Our study is the first investigating
the incidence of clopidogrel poor response at baseline versus that at
1 month as the primary endpoint and assessing the different
influence over time of genetic and environmental PR determi-
nants. Principally, 3 points were raised: the first concerns the
timing of measurements with respect to the last dose administra-
tion, the second refers to the occurrence of adverse events, and the
third touches on the independent determinants of bleeding.
Firstly, in our study, the maintenance dose of clopidogrel was
taken in the morning, and the blood sample to evaluate PR was
collected 1 to 5 h later. Considering both the time between drug
intake and blood sample and the degree of platelet reactivity
(PRU) value variation between “acute” and “chronic” phases, we
believe that the potential influence related to timing of measure-
ment may be minimal. Secondly, one of our aims was to assess the
predictive role of 1 month PRU value as compared to baselinevalue. So, as clearly reported in the Methods section, clinical events
that occurred after 1 month and up to 1 year of follow-up were
deliberately considered for this purpose. Patients with adverse
events during the first month were excluded. Third, it is plausible
that CYP2C19*17 carriership indicates a “chronic” tendency to
have lower PRU values. Nevertheless, other environmental factors
may still influence PRU values irrespective of *17 carriership. This
aspect could explain partially why both CYP2C19*17 and PRU
values emerged as independent predictors of bleeding complica-
tions. This observation is intriguing and deserves further investi-
gation, as it alone would strongly reinforce the concept that both
phenotype and genotype should integrate the clinical decision
making about the more appropriate choice of oral P2Y12 inhibitor.
Therefore, we agree with Dr. Jeong and colleagues when they
affirmed that, in the future, comprehensive algorithms including
clinical, genetic, and laboratory findings are needed to permit us to
optimize antiplatelet therapy in each individual patient. Our study
is one of the first efforts in this direction, and the value of
integrating this working algorithm into clinical practice versus a
purely clinically driven choice of P2Y12 inhibitor is currently being
tested as a pre-specified substudy of the MATRIX (Minimizing
Adverse Haemmhorragic Events by Transradial Access Site and
Systemic Implementation of Angiox) study.
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